Quell Therapeutics Enters a Collaborative Research Agreement with the Hannover Medical School

London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative research agreement with Hannover Medical School (MHH). Under the terms of the agreement, Quell Therapeutics will collaborate in joint research with MHH to accelerate the discovery and validation of multiple Chimeric Antigen Receptor (CAR)-Treg cell therapies.


The work will leverage the research of Quell co-founder, Elmar Jaeckel, MD, who is Group Leader “Immune tolerance” in the Department of Gastroenterology, Hepatology and Endocrinology at MHH. Dr. Jaeckel has focused his research interests on the discovery and validation of antigen-specific Treg cell therapies, and the role Tregs play in inducing tolerance to autoimmune responses and controlling inflammation in disease.

“We are excited to collaborate with Quell Therapeutics to develop antigen-specific CAR-Treg cell therapies for patients,” said Dr. Jaeckel. “Together we look forward to leveraging our CAR pipeline to validate CAR-Tregs and to demonstrate their ability to induce tolerance and control inflammation in murine models of disease.”

“Quell Therapeutics has the ambition to build out a pipeline of cell therapies leveraging our engineered Treg platform,” said Iain McGill, chief executive officer of Quell Therapeutics. “Collaborative research with MHH will enable us to leverage complementary interests to accelerate the development of our CAR-Treg products in autoimmune and inflammatory diseases, which we believe could offer patients transformative therapies to resolve chronic diseases.”

- Ends -

Further information:                                                                       

Julia Wilson

JW Communications

+44 (0) 7818 430877


About Quell Therapeutics

Quell Therapeutics is a privately held biotechnology company with a vision to become a leading engineered Tregs cell therapy company. The company is developing next generation engineered T regulatory (Treg) cell therapies for a range of diseases of immune dysfunction.

Quell Therapeutics was founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader “Immune tolerance” in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Back to News and insights